Title TBC
Objectives:
The principle of treat-to-target has proved successful in diverse disease, and the symposium will deep dive into treat-to-target approach in RA and its value to achieve early remission. Clinical evidence from research outcomes & real-world experience will further support treatment outcome optimization.
| Agenda - Saturday 31 October | |
|---|---|
|
|
Chairperson: Prof Seung-Ki Kwok, Republic of Korea
|
|
1025-1030 |
Opening remarks Prof Seung-Ki Kwok, Republic of Korea |
|
1030-1110 |
1. The value of Treat-to-target and early remission in RA and interpreting clinical evidence with Upadacitinib 2. The safety profile of Upadacitinib in RA 3. Real-world persistence of Upadacitinib in RA 4. Bridging evidence and clinical practice: My experience on clinical decision-making with Upadacitinib Prof Kunihiro Yamaoka, Japan |
|
1110-1120 |
|
|
1120-1125 |
Closing remarks Prof Seung-Ki Kwok, Republic of Korea |
